Easterly Government Properties Downgraded Post-Q2 Results: Analyst Foresees Limited Growth Ahead
RBC Capital Markets analyst Michael Carroll downgraded Easterly Government Properties Inc (NYSE: DEA) to Underperform from Sector Perform at a
Benzinga’s Top Ratings Upgrades, Downgrades For August 16, 2023
Upgrades UBS upgraded the previous rating for Aemetis Inc (NASDAQ:AMTX) from Neutral to Buy. For the second quarter,…
Design Therapeutics’ Modified DT-216 May Have Potential, But Analyst Awaits Further Developments
RBC Capital Market downgraded Design Therapeutics Inc (NASDAQ: DSGN) from Outperform to Sector Perform with a price target of $7,
Challenging Horizon For BioXcel: Analysts Dive Into Igalmi’s Potential And Reshaped Commercialization Strategy
Mizuho analyst Graig Suvannavejh downgraded BioXcel Therapeutics, Inc. (NASDAQ: BTAI) to Neutral from Buy,
AVID’s Acquisition Influences Analyst Downgrade: Unpacking The $1.4B Deal And Share Premiums
Truist Securities analyst Terry Tillman downgraded Avid Technology Inc's (NASDAQ: AVID) rating to
Bank Of America Says A Strategic Pause Is Necessary For The US Refiners – Here’s Why
BofA Securities analyst Doug Leggate said that the mid-cycle earnings power of the U.S. refining sector had been reset by a combination of capacity offshoring and a sustainable cost advantage of U.S. natural gas versus international peers.
Benzinga’s Top Ratings Upgrades, Downgrades For August 15, 2023
Upgrades Ladenburg Thalmann upgraded the previous rating for Edison International (NYSE:EIX) from Sell to Neutral. Edison Intl earned…
Benzinga’s Top Ratings Upgrades, Downgrades For August 14, 2023
Upgrades According to Barrington Research, the prior rating for Anika Therapeutics Inc (NASDAQ:ANIK) was changed from Market Perform…
Pfizer Collaboration Offers Potential Milestone Windfalls For TBIO, Despite Financial Hurdles: Analyst
KeyBanc Capital Markets analyst Paul Knight downgraded Telesis Bio, Inc. (NASDAQ: TBIO) to